Advertisement

Topics

Harpoon Therapeutics, Inc. Company Profile

23:14 EDT 21st September 2018 | BioPortfolio

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel T-cell recruiting drug discovery platform called TriTAC (tri-specific T-cell activating construct) to unleash the targeted cell-killing properties of a patient's own immune system through T-cell activation. This approach is being optimized to penetrate tissues and extend serum exposure, and has the potential to address a broad range of cancers, including solid tumors, and immunologic diseases. HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC biologic, is in development for the treatment of prostate cancer and is expected to enter a clinical trial in 2018. For more information, please visit www.harpoontx.com.


News Articles [733 Associated News Articles listed on BioPortfolio]

Harpoon Therapeutics treats first patient in Phase l trial of HPN424

Harpoon Therapeutics has treated the first patient in a Phase l clinical trial to investigate the safety, tolerability and pharmacokinetics...Read More... The post Harpoon Therapeutics treats first pa...

Harpoon Therapeutics Expands Board of Directors

Life Sciences Veteran Scott Myers Appointed to the Board of Directors Harpoon Therapeutics, Inc., an immuno-oncology company developing a new class of T cell engaging t...

Harpoon Therapeutics Announces Appointments to Board of Directors and Management Team

Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board Harpoon Therapeutics, Inc., a clinical-stage immuno-oncology company ...

Stand back, Aquaman: Harpoon-throwing satellite takes aim at space junk

Trilobites: Using Harpoon-Like Appendages, Bacteria ‘Fish’ for New DNA

Seeing how microbes snatch new genetic material from their environment could help in the fight against antibiotic resistance.

Harpoon Therapeutics Treats First Patient with HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

HPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA) Clinical Data Expected in 2019 Harpoon Therapeut...

Immunotherapy Pioneer and Serial Biotech Entrepreneur Patrick Baeuerle to Present Compelling Data from Harpoon Therapeutics’ Biotherapeutics Platform at the 2018 European Congress on Biotechnology

Patrick Baeuerle, Ph.D., a pioneer of T cell engaging therapies and executive partner at life sciences venture firm MPM Capital, will give a keynote presentation about next-genera...

Harpoon Therapeutics Launches Immuno-Oncology Pipeline With Compelling Data From Lead Programs at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Preclinical Data Showcase New T Cell Engaging Platform (TriTAC™) and Lead Drugs, HPN424 and HPN536, Targeting Prostate Cancer and Other Solid Tumors Harpoon Therapeut...

PubMed Articles [437 Associated PubMed Articles listed on BioPortfolio]

Hitting HIV's Harpoon.

The HIV-1 fusion peptide is a target for broadly neutralizing antibodies. In a recent issue of Nature Medicine, Xu et al. (2018) provide proof-of-concept that vaccination with fusion peptide followed...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Clinical Trials [154 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1257 Associated Companies listed on BioPortfolio]

Harpoon Therapeutics, Inc.

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is f...

Maverick Therapeutics Inc.

Maverick Therapeutics is pioneering the next generation of redirected T cell therapeutics in immuno-oncology. Maverick’s highly innovative platform is designed to deliver pot...

Harpoon Medical

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Harpoon Therapeutics, Inc." on BioPortfolio

We have published hundreds of Harpoon Therapeutics, Inc. news stories on BioPortfolio along with dozens of Harpoon Therapeutics, Inc. Clinical Trials and PubMed Articles about Harpoon Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Harpoon Therapeutics, Inc. Companies in our database. You can also find out about relevant Harpoon Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record